Our proprietary CombYSelect platform enables the rapid and reliable creation of IgG-like bispecific antibodies that target two tumor antigens simultaneously while maintaining a long, natural serum half-life. This approach simplifies therapeutic design, reduces the need for multi- antibody cocktails, and facilitates the engineering of advanced modalities—from dual-target bispecifics to functional Fc fusion proteins—supporting a versatile range of therapeutic designs. CombYSelect is also applicable to other isotypes, paving the way for next-generation, multi- modal therapies.

This platform also drives our bispecific antibody-drug conjugates (BADCs), which deliver potent, highly specific payloads—including cytotoxic agents, 7PB-100, and other innovative small molecules—directly to multiple tumor cells while minimizing side effects on healthy tissue.

Key Advantages:

• Dual antigen targeting for potent, tumor-specific cell killing

• Minimal, targeted mutations for rapid development, scalability, and high expression

• Customizable payloads for diverse cancer types

• Reduced risk of resistance through dual targeting and multifaceted mechanisms

• Low off-target toxicity and an enhanced safety profile